Independent associations between metabolic syndrome,diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study

Abstract

Diabetes mellitus (DM) has been termed a “coronary disease equivalent”, yet data suggest that only those DM subjects with metabolic syndrome (MetS) are at increased coronary risk.

Using data from the Dallas Heart Study, a large, probability-based population study, we assessed the individual and joint associations between MetS, DM and atherosclerosis, defined as coronary artery calcium (CAC) detected by electron-beam computerised tomography (EBCT) and abdominal aortic plaque (AAP) detected by magnetic resonance imaging.

Among 2,735 participants, the median age was 44 years; 1,863 (68%) were non-white; 1,509 (55%) were women; 697 (25.5%) had MetS without DM; 53 (1.9%) had DM without MetS; and 246 (9.0%) had both DM and MetS. The prevalence of CAC increased from those with neither MetS nor DM (16.6%) to MetS only (24.0%) to DM only (30.2%) to both MetS and DM (44.7%) (ptrend <0.0001). The prevalence of CAC was higher in those with both DM and MetS versus either alone (p<0.0001). After adjustment, MetS and DM were each independently associated with CAC (odds ratio [OR] 1.4, 95% confidence intervals [CI] 1.1–1.8; OR 1.8, 95% CI 1.3–2.5, respectively). Compared with the group without DM or MetS, those with both MetS and DM had the most CAC (adjusted OR 2.3; 95% CI 1.6–3.2). All analyses of AAP yielded qualitatively similar results.

In conclusion, both MetS and DM are independently associated with an increased prevalence of atherosclerosis, with the highest observed prevalence in subjects with both DM and MetS.

Keywords

atherosclerosis Dallas Heart Study diabetes mellitus metabolic syndrome

References

1. Wild S Roglic G , Green A , Sicree R , King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53.

2. Narayan KM Boyle JP , Geiss LS , Saaddine JB , Thompson JT. Impact of recent increase in incidence on future diabetes burden: US, 2005–2050. Diabetes Care 2006;29:2114–16.

3. Ford ES Giles WH , Dietz HW. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–9.

4. Meigs JB. Epidemiology of the metabolic syndrome, 2002. Am J Manag Care 2002;8(suppl):S283–S292; quiz S293–S296.

5. Haffner SM Lehto S , Ronnemaa T , Pyorala K , Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondia-betic subjects with and without prior myocardial infarction. N Engl J Med 1998;338:229–34.

6. Malmberg K Yusuf S , Gerstein HC et al. for the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2002;102:1014–19.

7. Grundy SM Cleeman JI , Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.

8. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1998;37:1595–607.

9. Alexander CM Landsman PB , Teutsch SM , Haffner MS. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–14.

10.

10. Dekker JM Girman C , Rhodes T et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112:666–73.

11.

11. Girman CJ Rhodes T , Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136–41.

12.

12. Isomaa B Almgren P , Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–9.

13.

13. Lakka HM Laaksonen DE , Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–16.

14.

14. Malik S Wong ND , Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245–50.

15.

15. Ninomiya JK L'Italien G , Criqui MH , Whyte JL , Gamst A , Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42–6.

16.

16. Olijhoek JK van der Graaf Y , Banga JD , Algra A , Rabelink TJ , Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004;25:342–8.

17.

17. Ingelsson E Sullivan LM , Murabito JM et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007;56:1718–26.

18.

18. Liu J Grundy SM , Wang W et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007;153:552–8.

19.

19. Hunt KJ Resendez RG , Williams K , Haffner SM , Stern PM. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251–7.

20.

20. Victor RG Haley RW , Willett DL et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004;93:1473–80.

21.

21. American Diabetes Association: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.

22.

22. Agatston AS Janowitz WR , Hildner FJ , Zusmer NR , Viamonte M Jr , Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32.

23.

23. Jain T Peshock R , McGuire DK et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol 2004;44:1011–17.

24.

24. Jaffer FA O'Donnell CJ , Larson MG et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002;22:849–54.

25.

25. Khera A de Lemos JA , Peshock RM et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006;113:38–43.

26.

26. Sone H Mizuno S , Fujii H et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005;28:1463–71.

27.

27. Onat A Ceyhan K , Basar O , Erer B , Toprak S , Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels – a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285–92.

28.

28. Bruno G Merletti F , Biggeri A et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004;27:2689–94.

29.

29. Ridker PM Buring JE , Cook NR , Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391–7.

30.

30. Lachman AS Spray TL , Kerwin DM , Shugoll GI , Roberts CW. Medial calcinosis of Monckeberg. A review of the problem and a description of a patient with involvement of peripheral, visceral and coronary arteries. Am J Med 1997;63:615–22.

31.

31. Lehto S Niskanen L , Suhonen M , Ronnemaa T , Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:978–83.

32.

32. Dziedzic-Goclawska A , Fuchs U , Krautschick I , Ostrowski K , Stachowicz W , Michalik J. Crystallinity of mineral deposited in arterial walls in the course of arteriosclerosis in diabetics and in patients with normal carbohydrate metabolism. Basic Appl Histochem 1984;28:21–8.

33.

33. Raggi P Shaw LJ , Berman DS , Callister QT. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004;43:1663–9.

34.

34. Olson JC Edmundowicz D , Becker DJ , Kuller LH , Orchard TJ. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000;49:1571–8.

35.

35. Cleary PA Orchard TJ , Genuth S et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556–65.

36.

36. Colhoun HM Rubens MB , Underwood SR , Fuller HJ. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol 2000;36:2160–7.

37.

37. Dabelea D Kinney G , Snell-Bergeon JK et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003;52:2833–9.

38.

38. Snell-Bergeon JK , Hokanson JE , Jensen L et al. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care 2003;26:2923–8.